SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 250 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $212,629 | -56.5% | 7,712 | -52.5% | 0.00% | – |
Q2 2023 | $488,467 | -60.1% | 16,250 | -51.9% | 0.00% | – |
Q1 2023 | $1,224,672 | +298.1% | 33,802 | +292.0% | 0.00% | – |
Q4 2022 | $307,618 | -75.3% | 8,624 | -76.6% | 0.00% | – |
Q3 2022 | $1,246,000 | +18.8% | 36,799 | +1.4% | 0.00% | – |
Q2 2022 | $1,049,000 | -23.7% | 36,280 | -14.7% | 0.00% | – |
Q1 2022 | $1,374,000 | -81.4% | 42,509 | -83.3% | 0.00% | -100.0% |
Q4 2021 | $7,403,000 | -8.8% | 253,901 | -16.6% | 0.00% | 0.0% |
Q3 2021 | $8,119,000 | -78.7% | 304,413 | -75.5% | 0.00% | -66.7% |
Q2 2021 | $38,182,000 | +81.1% | 1,240,095 | +53.9% | 0.00% | +50.0% |
Q1 2021 | $21,089,000 | +49.9% | 805,574 | +44.1% | 0.00% | +100.0% |
Q4 2020 | $14,070,000 | +405.9% | 559,199 | +319.2% | 0.00% | – |
Q3 2020 | $2,781,000 | -12.3% | 133,409 | -0.1% | 0.00% | – |
Q2 2020 | $3,172,000 | +37.0% | 133,533 | +3.7% | 0.00% | – |
Q1 2020 | $2,316,000 | -79.0% | 128,727 | -72.3% | 0.00% | -100.0% |
Q4 2019 | $11,018,000 | -21.1% | 464,514 | -8.6% | 0.00% | -50.0% |
Q3 2019 | $13,960,000 | -36.1% | 508,028 | -23.1% | 0.00% | -33.3% |
Q2 2019 | $21,851,000 | -15.4% | 660,357 | -10.4% | 0.00% | 0.0% |
Q1 2019 | $25,826,000 | -62.7% | 737,068 | -64.6% | 0.00% | -66.7% |
Q4 2018 | $69,174,000 | -42.1% | 2,082,315 | -12.2% | 0.01% | -30.8% |
Q3 2018 | $119,396,000 | +111.9% | 2,371,321 | +151.9% | 0.01% | +116.7% |
Q2 2018 | $56,337,000 | +2526.4% | 941,300 | +1909.6% | 0.01% | – |
Q1 2018 | $2,145,000 | +0.4% | 46,841 | -12.6% | 0.00% | – |
Q4 2017 | $2,136,000 | -19.0% | 53,600 | -18.7% | 0.00% | – |
Q3 2017 | $2,636,000 | -41.3% | 65,900 | -36.7% | 0.00% | -100.0% |
Q2 2017 | $4,487,000 | +37.7% | 104,100 | 0.0% | 0.00% | – |
Q1 2017 | $3,258,000 | -9.7% | 104,100 | -27.2% | 0.00% | – |
Q4 2016 | $3,608,000 | -74.1% | 142,900 | -74.6% | 0.00% | -100.0% |
Q3 2016 | $13,930,000 | -36.2% | 563,300 | -47.5% | 0.00% | -33.3% |
Q2 2016 | $21,849,000 | +13.6% | 1,072,600 | -15.0% | 0.00% | 0.0% |
Q1 2016 | $19,241,000 | +226.3% | 1,261,700 | +187.6% | 0.00% | +200.0% |
Q4 2015 | $5,896,000 | -4.2% | 438,700 | +0.0% | 0.00% | 0.0% |
Q3 2015 | $6,152,000 | -20.0% | 438,500 | -3.2% | 0.00% | 0.0% |
Q2 2015 | $7,692,000 | – | 453,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |